

Children, Adolescent, and Adult COVID-19 Vaccine Dosage and Scheduling Table

Brand	Primary Series			Additional Dose for Primary Series			Booster Dose*			
	Age (y)	Dose (volume)	No. doses (interval)	Age (y)	Dose (volume)	No. doses (interval)	Age (y)	Dose (volume)	No. doses (interval)	
Pfizer	5-11	10 μg (0.2 mL)	2 (21 d)	5-11	N/A (---)	N/A (---)	5-15	N/A (---)	N/A (---)	
	12+	30 μg (0.3 mL)	2 (21 d)	12+	30 μg (0.3 mL)	1 (≥ 28 d)	16+	30 μg (0.3 mL)	1 (≥ 6 m)	
				Authorized for: • Persons with solid organ transplants, or diagnosed with conditions considered to have an equivalent level of immunocompromise.			Authorized for: • Persons aged 16 years and older			
	Dose #1 ----->Dose #2----->Dose #3 (certain individuals)----->Booster (16 years and older) 21 days 28 days ≥6 months									
Moderna	18+	100 μg (0.5 mL)	2 (28 d)	18+	100 μg (0.5 mL)	1 (≥ 28 d)	18+	50 μg (0.25 mL)	1 (≥ 6 m)	
				Authorized for: • Persons with solid organ transplants, or diagnosed with conditions considered to have an equivalent level of immunocompromise.			Authorized for: • Persons aged 18 years and older			
	Dose #1 ----->Dose #2----->Dose #3 (certain individuals)----->Booster (18 years and older) 28 days 28 days ≥6 months									
J&J/ Janssen[†]	18+	5 × 10 VP (0.5 mL)	1 (N/A)	Not authorized			18+	5 × 10 VP (0.5 mL)	1 (≥ 2 m)	
							Authorized for: • Persons aged 18 years and older			
	Dose #1 ----->Booster (18 years and older) ≥ 2 months									

No. = number, y = years, mL = milliliters, m = months, d = days, μg = micrograms, VP= viral particles

* For [persons eligible to receive a COVID-19 booster](#), the timing of when that booster should be administered is determined by the primary series the person received.

[†]As of December 16, 2021, CDC recommends mRNA vaccines (i.e., Pfizer and Moderna) over the J&J vaccine to prevent COVID-19 in persons 18 years and older. This preference applies to both the primary series and booster dose.

Adult Heterologous* COVID-19 Booster Dose Table

Primary Series Brand [§]	Booster Vaccine Brand [†]								
	Dose	Pfizer Time	Age	Dose	Moderna Time	Age	Dose	J&J/Janssen Time	Age
Pfizer	30 µg (0.3mL)	≥ 6 m	18+	50 µg (0.25mL)	≥ 6 m	18+	5×10 VP (0.5mL)	≥ 6 m	18+
Moderna	30 µg (0.3mL)	≥ 6 m	18+	50 µg (0.25mL)	≥ 6 m	18+	5×10 VP (0.5mL)	≥ 6 m	18+
J&J/Janssen [¶]	30 µg (0.3mL)	≥ 2 m	18+	50 µg (0.25mL)	≥ 2 m	18+	5×10 VP (0.5mL)	≥ 2 m	18+

* Also referred to as “mix and match.”

† The booster vaccine dose should be guided by the booster vaccine brand being administered.

§ For [persons eligible to receive a COVID-19 booster](#), the timing of when that booster should be administered is determined by the primary series the person received.

¶ As of December 16, 2021, CDC recommends mRNA vaccines (i.e., Pfizer and Moderna) over the J&J vaccine to prevent COVID-19 in persons 18 years and older. This preference applies to both the primary series and booster dose.

Additional Notes:

- Heterologous (mix and match) booster doses can be used for individuals 18 years and older. The use of an mRNA COVID-19 vaccine for a booster dose is preferred even for those who received the J&J vaccine as their primary series; however, in most situations, offering the J&J vaccine is preferable to not providing a booster dose at all.
- Potential risks of an mRNA COVID-19 booster dose include the rare risks of myocarditis and pericarditis. Based on current data, the group at the highest risk for myocarditis and pericarditis are males aged <30 years.
- Potential risks of a J&J COVID-19 booster include the rare risks of thrombosis with thrombocytopenia syndrome (TTS) and Guillain-Barré Syndrome (GBS). Based on current data, the group at the highest risk for GBS are males aged 50-64 years and the group at highest risk for TTS are women aged 30-49 years. Anyone who is considering the J&J vaccine should be informed that mRNA vaccines are preferred over J&J and be made aware of the rare risk of TTS after J&J vaccination and the need to seek immediate medical care if symptoms develop. People who developed TTS after their initial J&J vaccine should not receive a J&J booster dose.
- 16-and-17-year-olds who completed the Pfizer primary series can receive a Pfizer booster dose only.
- Moderately and severely immunocompromised people ≥16 years who received an additional mRNA vaccine dose can receive a single COVID-19 booster dose at least 6 months after completing their additional mRNA vaccine dose.
- Refer to [CDC Clinical Considerations](#) for additional guidance.